In the US, Dovato is indicated as a complete regimen to treat HIV-1 infection in adults with no ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed ...

ViiV Healthcare tapped real patients to help drill down into Dovato’s unique selling point to help promote the HIV drug—and it took that message far and wide with a boost in TV ad spending during ...

The MarketWatch News Department was not involved in the creation of this content. -- Dovato is now the first and only oral, two-drug, single-tablet regimen available for people aged 12 and older ...

Findings showed 26 of the 30 participants achieved and maintained viral suppression (HIV-1 RNA 50c/mL) at week 48. The Food and Drug Administration (FDA) has expanded ...

HIV is a lifelong infection that affects many people. People with HIV take many different types of medicines to help control their condition and to prevent the infection from developing into AIDS.

People with HIV are more than their diagnosis, of course. However, GlaxoSmithKline's ViiV figured out a creative way to get that message across in its Dovato DTC campaign—and nabbed the #FierceMadness ...

Credit: ViiV Healthcare. The new blister pack is a monthly 30-count box containing 5 sheets of tablets; each sheet is perforated and is about "the size of a credit card" offering more discreet ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented 48-week data from the SALSA ...

Dovato is a complete treatment for HIV in certain adults and children, taken as 1 tablet per day. Dovato’s side effects can range from mild issues like headache and nausea to more serious ones, such ...